为什么在最先进的筛查项目中仍会发生宫颈癌?
研究分析Kaiser Permanente Northern California(KPNC)自2003年起对≥30岁女性每三年一次HPV与细胞学联合检测的宫颈癌筛查项目,回顾623例宫颈癌诊断前的临床病史以判定癌症原因。癌症罕见且多为局部可治疗期,57.8%为流行性诊断;程序有效性为95.3%,鳞状细胞癌高于腺癌且随年龄增长而下降。
要点
- 623例宫颈癌中57.8%为流行性诊断(首次联合检测一年内局部期或两年内区域/远处期诊断)。
- 不依从筛查和管理、假阴性联合检测/采样错误、假阴性组织学诊断、治疗失败分别先于9.0%、11.2%、9.0%、4.3%的癌症。
- 程序有效性95.3%,鳞状细胞癌高于腺癌(p<0.0001),且随年龄增长而下降(ptrend<0.0001)。
核心结论
- 最先进的强化筛查项目导致的宫颈癌极少,其中大多数通过筛查早期发现。
- 筛查在较大年龄可能变得效率较低。
研究设计与样本
- 回顾性分析KPNC自2003年起对>1,000,000名≥30岁女性每三年一次HPV与细胞学联合检测的宫颈癌筛查项目。
- 回顾宫颈癌诊断前的临床病史以判定癌症原因,计算程序有效性和诊断产出的替代指标。
主要发现
- 623例有至少一次 preceding 或同期联合检测的宫颈癌中,360例(57.8%)被判定为流行性(首次联合检测一年内局部期或两年内区域/远处期诊断)。
- 不依从推荐筛查和管理先于所有癌症的9.0%;假阴性联合检测/采样错误(HPV和细胞学阴性)、假阴性组织学诊断、治疗失败分别先于所有癌症的11.2%、9.0%、4.3%。
- 癌症原因按组织学类别存在显著异质性(所有p<0.001;排除流行性病例后p=0.002)。
- 程序有效性(95.3%)和诊断产出在鳞状细胞癌高于腺癌(p<0.0001),且两者均随年龄增长而下降(ptrend<0.0001)。
关键数值与推荐
- 程序有效性定义为癌前病变/(癌前病变+癌症),总体为95.3%。
- 诊断产出定义为每1000次联合检测的癌前病变和癌症数。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The goal of cervical screening is to detect and treat precancers before some become cancer. We wanted to understand why, despite state-of-the-art methods, cervical cancers occured in relationship to programmatic performance at Kaiser Permanente Northern California (KPNC), where >1,000,000 women aged ≥30years have undergone cervical cancer screening by triennial HPV and cytology cotesting since 2003. METHODS: We reviewed clinical histories preceding cervical cancer diagnoses to assign "causes" of cancer. We calculated surrogate measures of programmatic effectiveness (precancers/(precancers and cancers)) and diagnostic yield (precancers and cancers per 1000 cotests), overall and by age at cotest (30-39, 40-49, and ≥50years). RESULTS: Cancer was rare and found mainly in a localized (treatable) stage. Of 623 cervical cancers with at least one preceding or concurrent cotest, 360 (57.8%) were judged to be prevalent (diagnosed at a localized stage within one year or regional/distant stage within two years of the first cotest). Non-compliance with recommended screening and management preceded 9.0% of all cancers. False-negative cotests/sampling errors (HPV and cytology negative), false-negative histologic diagnoses, and treatment failures preceded 11.2%, 9.0%, and 4.3%, respectively, of all cancers. There was significant heterogeneity in the causes of cancer by histologic category (p<0.001 for all; p=0.002 excluding prevalent cases). Programmatic effectiveness (95.3%) and diagnostic yield were greater for squamous cell versus adenocarcinoma histology (p<0.0001) and both decreased with older ages (ptrend<0.0001). CONCLUSIONS: A state-of-the-art intensive screening program results in very few cervical cancers, most of which are detected early by screening. Screening may become less efficient at older ages.
引用
- Castle PE, Kinney WK, Cheung LC, et al. Why does cervical cancer occur in a state-of-the-art screening program? Gynecol Oncol. 2017. PMID: 28606721. doi:10.1016/j.ygyno.2017.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。